NASDAQ:KRYS Krystal Biotech Q2 2026 Earnings Report $363.28 -0.95 (-0.26%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$363.68 +0.41 (+0.11%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Krystal Biotech EPS ResultsActual EPSN/AConsensus EPS $1.70Beat/MissN/AOne Year Ago EPSN/AKrystal Biotech Revenue ResultsActual RevenueN/AExpected Revenue$121.83 millionBeat/MissN/AYoY Revenue GrowthN/AKrystal Biotech Announcement DetailsQuarterQ2 2026Date8/3/2026TimeBefore Market OpensConference Call DateMonday, August 3, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Krystal Biotech Earnings HeadlinesKrystal Biotech: International Expansion And A Vibrant PipelineJuly 29 at 8:00 AM | seekingalpha.comKrystal Biotech: Profitable, Self-Funding, And Loaded With OptionalityJuly 29 at 6:00 AM | seekingalpha.comGet “backdoor access” BEFORE the next big IPOWall Street insiders always get first access to pre-IPO shares at the lowest prices, locking in gains before the public ever sees a listing. Dr Mark Skousen says he's found a crack in that system - a backdoor that could let everyday investors get a pre-IPO stake before the announcement hits. Space is limited, and Dr Skousen is revealing the ticker for free right now. | The Oxford Club (Ad)Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026July 23, 2026 | globenewswire.comS&P Dow Jones Indices: Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600July 21, 2026 | finanznachrichten.deKrystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)June 25, 2026 | finance.yahoo.comSee More Krystal Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Krystal Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Krystal Biotech and other key companies, straight to your email. Email Address About Krystal BiotechKrystal Biotech (NASDAQ:KRYS) is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments. The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts. Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.View Krystal Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to Come Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
